Oxytocin Spray 10 mg

One-Peptides OXYTOCIN 10 mg — OXTR nonapeptide nasal spray for laboratory research

OXYTOCIN 10 mg nasal spray is a research reagent (Research Use Only) supplied as a pre-dissolved solution. This product is a synthetic nonapeptide intended solely for laboratory research into oxytocin receptor (OXTR) signalling and social neurobiology. It is not a medicine, a dietary supplement or a product for human use. Although oxytocin as an injectable substance (Syntocinon, Oxytocin) is an authorised obstetric medicine, this RUO reagent in spray form belongs to a separate regulatory framework — it is not a medicinal product and does not replace any medicine. The entire description concerns receptor pharmacology and findings reported in the literature; it does not and cannot contain any claims of “bonding”, “treating anxiety, depression or autism” or any other health effect in humans.

Oxytocin is one of the earliest characterised and most widely studied peptides in the history of neuroendocrinology — and, at the same time, one of those around which the greatest number of oversimplifications has accumulated. In 1953 Vincent du Vigneaud synthesised it as the first peptide hormone obtained chemically, which two years later earned him the Nobel Prize. For decades it was associated almost exclusively with two classic physiological functions — uterine contractions during labour and the stimulation of lactation. It was only from the 1990s onwards that research teams began systematically describing another side of this peptide: its role in the brain as a neuromodulator of social behaviour, social cognition and the regulation of the stress response.

In the One Peptides catalogue, oxytocin is supplied as a chemical reagent for research use only (RUO) in the format of a pre-dissolved nasal spray. The choice of this form is not incidental: intranasal administration is one of the most intensively explored directions in human oxytocin research, described in the context of the nose–brain axis. The solution does not require reconstitution of a lyophilisate, and the dosing system allows for the reproducible withdrawal of the peptide under controlled conditions. This is a technical solution for teams working on OXTR signalling and social neurobiology in research models — not a form intended for administration to humans.

Oxytocin is a natural nonapeptide (nine amino acids) with a cyclic structure closed by a disulphide bridge, and an agonist of the oxytocin receptor (OXTR). It is produced in neurons of the hypothalamus and released by the posterior lobe of the pituitary gland. In neurobiology it is studied as a modulator of social behaviour, bonding, social cognition and the stress response. In laboratory circulation it is available solely as a research reagent (RUO).

What oxytocin is — sequence and class

Oxytocin is one of the smallest biologically active regulatory peptides in the body. Its amino acid sequence reads Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, and its characteristic structural feature is a disulphide bridge linking the cysteine residues at positions 1 and 6. This bridge closes a six-amino-acid ring, from which a three-amino-acid “tail” (Pro-Leu-Gly-NH₂) protrudes, terminating in an amide group. It is precisely this compact, rigidified structure that determines how the peptide binds to its receptor.

The target receptor is OXTR — the oxytocin receptor belonging to the family of G protein-coupled receptors (GPCRs). It occurs both in peripheral tissues (uterus, mammary gland) and in numerous structures of the central nervous system, including areas involved in processing social and emotional stimuli. Structurally, oxytocin is very close to vasopressin (they differ by only two amino acids at positions 3 and 8), which translates into a degree of mutual cross-activity of both peptides towards their receptors — an important detail when interpreting the results of receptor studies.

Naturally, oxytocin is synthesised in neurons of the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) of the hypothalamus, from where it is transported axonally to the posterior lobe of the pituitary gland and released into circulation in response to stimuli. In addition to this classic neurohormonal route, direct oxytocinergic projections from the PVN to brain structures have also been identified — these form the anatomical basis for interest in oxytocin as a central neuromodulator.

Chemical characteristics

Mechanism of action in research

Oxytocin exerts its action through agonism of the OXTR receptor. Binding of the peptide to the G protein-coupled receptor triggers an intracellular signalling cascade — depending on the cell type, primarily the Gq protein/phospholipase C pathway, leading to the mobilisation of intracellular calcium. In peripheral tissues this translates into classic physiological effects (contraction of smooth muscle), whereas in the central nervous system OXTR signalling is studied in an entirely different context — as a modulator of the activity of neuronal circuits involved in processing social stimuli.

In the neurobiological literature, oxytocin is described as a neuromodulator of social behaviour. Research on OXTR signalling focuses on several areas: social cognition (the recognition and processing of social signals), the response to stimuli related to bonding, and the regulation of the stress response. In animal models, the role of oxytocin in the formation of pair bonds in monogamous species has been analysed, among other things, as well as its influence on the activity of limbic structures, including the amygdala — a structure central to the processing of emotion and the fear response.

An important interpretative caveat: the central mechanism of oxytocin is complex and context-dependent. Contemporary literature has moved away from the simple narrative of “the more oxytocin, the more trust” towards a picture in which the effects of OXTR signalling depend on the social context, the baseline state of the organism and the specific neuronal circuit. The reference data come from in vitro receptor studies, animal models and controlled studies involving humans conducted at academic centres — and describe how the system works, not any application beyond the laboratory.

Nasal spray format — research context

Here the format has a genuine scientific rationale. Of all neuroactive peptides, intranasal oxytocin is one of the most intensively studied directions in humans — there is an extensive body of literature analysing the influence of intranasal administration on social cognition, the processing of emotional stimuli and the stress response under controlled conditions. The reason for interest in this route is the concept of the nose–brain axis: the richly vascularised and innervated nasal mucosa, adjacent to the olfactory pathways and the trigeminal nerve, is sometimes considered a potential route for transporting molecules to the central nervous system with limited involvement of the general circulation.

The nasal spray format makes the same reagent available as a pre-dissolved solution intended for research into intranasal administration. The solution does not require reconstitution — it is ready for laboratory work in accordance with the experimental plan, and the dosing system ensures reproducibility of withdrawal.

Full honesty about the scientific status of this route is, however, necessary. Despite the large number of publications, the mechanism and reproducibility of the effects of intranasal oxytocin remain the subject of active debate and replication. Some studies have not confirmed earlier observations, and questions about how much of the peptide actually reaches brain structures after intranasal administration still have no unambiguous answer. The format should therefore be treated as a tool for research into this route of administration, rather than as a pathway with an established, confirmed profile in humans.

Oxytocin RUO vs oxytocin as a medicine

The same molecule operates within two entirely separate regulatory frameworks, which must not be confused. The comparison below sets out the difference.

The conclusion is unambiguous: the fact that oxytocin exists as an authorised injectable medicine in obstetrics does not make the RUO reagent in spray form a medicine. This product is not a medicinal product, has no obstetric application and cannot be regarded as a substitute for any medical preparation. It is a laboratory tool — and remains solely that.

Applications in scientific research

Oxytocin is one of the few neuropeptides to have been the subject of a broad research programme — from the receptor level to controlled trials involving humans at academic centres. The overview below is purely scientific in nature: it describes what has been studied, and does not suggest any application beyond the laboratory.

OXTR receptor pharmacology. The fundamental direction is the characterisation of oxytocin binding to the OXTR receptor and the signalling cascade triggered following activation. In vitro receptor studies analyse affinity, selectivity relative to related vasopressin receptors and the dynamics of the cellular response — this is the foundation for interpreting all observations at higher levels of organisation.

Models of social behaviour. In animal models, oxytocin is a tool for studying the neurobiology of bonding and prosocial behaviour. Classic experiments in monogamous species (prairie voles) demonstrated the involvement of oxytocin signalling in the formation of pair bonds, opening up an entire field of research into the neuronal basis of social behaviour.

Stress neurobiology and social cognition. A separate area is the role of oxytocin in regulating the stress response and in processing social stimuli. Brain imaging studies (fMRI) in humans have analysed the modulation of the activity of limbic structures, including the amygdala, in response to social and emotional stimuli — as research into the mechanism of action of the system, rather than confirmation of any therapeutic effect.

The interpretative framework remains unambiguous: these are studies of physiology and mechanism, conducted under controlled conditions, often in small groups, assessing the acute response of the system to administration of the peptide. They are not authorisation studies nor material justifying use beyond the laboratory.

One Peptides quality specification

Every batch of oxytocin nasal spray undergoes a full process of analytical control.

• HPLC ≥98% — the main peak area is ≥98% of the sum of areas (liquid chromatography with UV detection).
• MS confirmation — confirmation of peptide identity by mass spectrometry (theoretical mass ~1007 Da).
• COA per batch — a certificate of analysis for each batch (theoretical and measured mass, HPLC profile, date of synthesis, batch number).
• Cold chain 2–8°C — a refrigerated chain with monitoring from synthesis to delivery; oxytocin in solution is thermally sensitive, which is why temperature control matters for preserving the integrity of the peptide.
• Batch traceability — the batch number in three places: label, invoice and COA.

The reagent is intended solely for laboratory applications — without any therapeutic claims and without intended use for administration to humans. The preparation of working solutions should be carried out in accordance with the experimental plan and the procedures adopted in the laboratory.

Safety and limitations

All the information below comes from academic research into the physiology and neurobiology of oxytocin and does not constitute a recommendation to use this reagent in humans. This product is not a medicine or a supplement.

In published studies involving volunteers, intranasal oxytocin administered within a short window, under controlled conditions and under supervision, was generally well tolerated — authors reported a favourable profile under acute exposure, with no signals of serious events at the exposures used in experiments. This observation, however, applies strictly to research conditions: supervision, single or short-term administrations and selected groups of participants.

What the literature does not resolve:

• A lack of data on long-term intranasal exposure in humans — studies have focused on the acute, short-term response. The profile under chronic intranasal administration remains uncharacterised.
• Uncertainty about central bioavailability — how much of the peptide actually reaches brain structures after intranasal administration remains the subject of debate; the mechanism of the nose–brain axis is not fully confirmed.
• Limited reproducibility of behavioural effects — some observations on social cognition have not been unambiguously replicated; the scientific picture is more nuanced than the early literature suggested.
• Cross-activity with the vasopressin system — the close structural relationship with vasopressin complicates the unambiguous interpretation of some receptor effects.

In practice this means a conditional framework: the data suggest good tolerability under narrowly defined experimental conditions, but no material exists to justify safety beyond them. In laboratory circulation, oxytocin in this form remains solely a research reagent.

Regulatory status and WADA

Oxytocin RUO (this product) — a Research Use Only research reagent in the chemical reagent trade. The label reads “For research use only. Not for human use”. In this form it is not a medicinal product, a dietary supplement or a foodstuff, and it holds no authorisation as a medicine or supplement.

Oxytocin as a medicine — the above should be distinguished from the status of oxytocin as an authorised medicinal product (Syntocinon, Oxytocin) administered by injection in obstetrics. This is a separate regulatory framework: the authorisation of an injectable medicine for medical applications does not apply to the RUO reagent in spray form and in no way legitimises its use in humans.

WADA. Oxytocin does not appear as a separate entry on the current WADA prohibited list. Its status may change in subsequent editions, and the general clauses concerning biologically active substances require independent verification by the researcher.

Frequently asked questions

What is oxytocin?
Oxytocin is a natural nonapeptide — a peptide built from nine amino acids with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, with a characteristic disulphide bridge closing the ring. It is an agonist of the oxytocin receptor (OXTR), is produced in neurons of the hypothalamus and is released by the posterior lobe of the pituitary gland. In neurobiology it is studied as a modulator of social behaviour, social cognition and the stress response. In the One Peptides catalogue it functions solely as a research reagent (RUO).

How does the RUO spray differ from the medicine Syntocinon?
These are two entirely separate regulatory frameworks for the same molecule. Syntocinon (and the analogous Oxytocin preparations) is an authorised injectable medicine used in obstetrics — in the induction and augmentation of labour and the support of lactation, under medical supervision. This product is a research reagent in the form of a pre-dissolved nasal spray, intended solely for laboratory research into OXTR signalling. It is not a medicine, has no obstetric application and does not replace any medical preparation.

Is oxytocin the “love hormone”?
The colloquial label “love hormone” or “cuddle hormone” appeared in popular-science media, but it is a misleading oversimplification — and it does not describe this product. From a scientific perspective, oxytocin is an OXTR receptor agonist studied as a neuromodulator of social behaviour, and contemporary literature has moved away from the simple narrative of “the more oxytocin, the more love” towards a picture that is strongly context-dependent. In the One Peptides catalogue it is a research reagent (RUO) without any claims of building bonds or emotions in humans.

What does research say about oxytocin and social cognition?
There is an extensive body of literature analysing the influence of intranasal oxytocin on social cognition — the recognition and processing of social signals, the response to emotional stimuli and the activity of limbic structures in brain imaging studies (fMRI). These are studies of the mechanism of action of the system, conducted under controlled conditions, often in small groups. It should be borne in mind that some observations have not been unambiguously replicated, and the reproducibility and mechanism of intranasal effects remain the subject of active scientific debate.

Why is oxytocin available in a nasal spray format and how should it be stored?
The nasal spray makes the reagent available as a pre-dissolved solution intended for research into intranasal administration — without the need to reconstitute a lyophilisate. The format has a genuine research rationale, because the intranasal route and the nose–brain axis are among the most intensively explored directions in human oxytocin research. The solution is thermally sensitive, which is why it is stored in a cold chain at 2–8°C. The format is intended solely for laboratory work.

Bibliography

1. Meyer-Lindenberg A et al. (2011). Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
2. Heinrichs M et al. (2009). Oxytocin, vasopressin, and human social behavior
3. Review: Intranasal oxytocin and social cognition — a systematic review (review; no verified DOI)
4. Jurek B, Neumann ID (2018). The oxytocin receptor: from intracellular signaling to behavior

Oxytocin 10 mg nasal spray in the One Peptides catalogue is a reagent intended solely for laboratory and scientific research (Research Use Only). It is not a medicine, a dietary supplement or a product intended for consumption or administration by humans. Nor is it a therapy for social disorders, autism, anxiety or depression, and it does not serve to “build bonds” in humans — the description refers solely to the pharmacology of the OXTR receptor and findings reported in the scientific literature. It should be distinguished from oxytocin as an authorised injectable medicine used in obstetrics (Syntocinon, Oxytocin) — that is a separate regulatory framework, and this RUO reagent is not a medicinal product and does not replace any medicine. The information is educational and scientific in nature and does not constitute medical or pharmaceutical advice or instructions for administration. The reagent is not intended for use in humans.

RUO category: Oxytocin collects products associated with this molecule.